Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viracta Therapeutics Inc VIRX

Healthcare Biotechnology
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated... see more

Recent & Breaking News (NDAQ:VIRX)

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 13, 2024

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

GlobeNewswire November 6, 2024

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 3, 2024

Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 14, 2024

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

GlobeNewswire August 14, 2024

Viracta Therapeutics Announces New Employment Inducement Grants

GlobeNewswire May 17, 2024

Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

GlobeNewswire May 14, 2024

Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 9, 2024

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 7, 2024

Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma

GlobeNewswire April 15, 2024

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

GlobeNewswire April 1, 2024

Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 7, 2024

Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial

GlobeNewswire February 29, 2024

Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire February 6, 2024

Viracta Therapeutics Provides Clinical Update and Outlook for 2024

GlobeNewswire January 4, 2024

Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma

GlobeNewswire December 12, 2023

Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels

GlobeNewswire December 4, 2023

Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 9, 2023

Viracta Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 7, 2023

Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers

GlobeNewswire October 4, 2023